KAREM F. ABDELMOETY, M.D., M., MOSTAFA, M.D., A. (2021). Comparative Study between Rivaroxaban and Warfarin inTreatment of Patients with Recurrent Deep Venous Thrombosis. The Medical Journal of Cairo University, 89(March), 199-207. doi: 10.21608/mjcu.2021.153789
MOHAMED M.R. YOUSEF, M.Sc.; KAREM F. ABDELMOETY, M.D.; ASHRAF A. MOSTAFA, M.D.. "Comparative Study between Rivaroxaban and Warfarin inTreatment of Patients with Recurrent Deep Venous Thrombosis". The Medical Journal of Cairo University, 89, March, 2021, 199-207. doi: 10.21608/mjcu.2021.153789
KAREM F. ABDELMOETY, M.D., M., MOSTAFA, M.D., A. (2021). 'Comparative Study between Rivaroxaban and Warfarin inTreatment of Patients with Recurrent Deep Venous Thrombosis', The Medical Journal of Cairo University, 89(March), pp. 199-207. doi: 10.21608/mjcu.2021.153789
KAREM F. ABDELMOETY, M.D., M., MOSTAFA, M.D., A. Comparative Study between Rivaroxaban and Warfarin inTreatment of Patients with Recurrent Deep Venous Thrombosis. The Medical Journal of Cairo University, 2021; 89(March): 199-207. doi: 10.21608/mjcu.2021.153789
Comparative Study between Rivaroxaban and Warfarin inTreatment of Patients with Recurrent Deep Venous Thrombosis
The Department of General Surgery, Faculty of Medicine, Ain Shams University
Abstract
AbstractBackground: Venous Thrombo-Embolism (VTE) manifestsas Deep Venous Thrombosis (DVT) and/or Pulmonary Em-bolism (PE). Per 1000 persons in the general population, theannual incidence is 1 to 2 cases. For decades, the gold standard of anti-thrombotic therapy has been based on heparins and Vitamin K Antagonists (VKAs), their narrow therapeutic range and multiple interactions led to the development of New Oral Anticoagulants (NOACs) beginning in 2003. Two types of new anticoagulants have been developed: Direct factor Xa inhibitors (Rivaroxaban) and direct factor IIa (thrombin) inhibitors.Aim of Study: The aim of this study was to comparerivaroxaban versus warfarin in treatment of recurrent DVTas regard efficacy, safety and complications.Patients and Methods: This was a prospective studyconducted on 30 patients suffering from recurrent deep venousthrombosis. The studied cases were divided into two groups,Group A treated by rivaroxaban, while group B treated bywarfarin over a period of 6 months. All cases were subjectedto full history taking, complete general and local examination,routine laboratory investigations and Duplex Scanning.Results: No statistically significant differences amongrivaroxaban and warfarin groups as regards presence of riskfactors, DVT extension, duplex results and incidence ofcomplications, while there was significant difference as regardsduration till symptoms relief.Conclusion: Rivaroxaban seems to have same efficacyas warfarin with advantage being earlier in symptoms relief/days, recanalization and patient compliance. In addition,warfarin users need to be monitored regularly.
Top